Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Apr;22(4):310-8.
doi: 10.1097/FPC.0b013e32834f94cb.

Celecoxib pathways: pharmacokinetics and pharmacodynamics

Li Gong  1 , Caroline F Thorn, Monica M Bertagnolli, Tilo Grosser, Russ B Altman, Teri E Klein
Affiliations

Celecoxib pathways: pharmacokinetics and pharmacodynamics

Li Gong et al. Pharmacogenet Genomics. 2012 Apr.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflicts of interest

There are no conflicts of interest.

Figures

Fig. 1
Fig. 1
Hepatic metabolism of celecoxib. ADH, alcohol dehydrogenases; UGTs, UDP glucuronosyltransferases. A fully interactive version is available online at http://www.pharmgkb.org/pathway/PA165816736.
Fig. 2
Fig. 2
Stylized cell depicting the mechanism of action of celecoxib and candidate genes interacting with celecoxib and involved in the proposed anticancer mechanisms of celecoxib, including induction of apoptosis, cell cycle arrest, regulation of angiogenesis, and induction of endoplasmic reticulum (ER) stress. CACN: L-type calcium channels; KCNQ: voltage-gated potassium channels; MMP9, metalloproteinase; NSAIDs, nonsteroidal anti-inflammatory drugs; PGH2, prostaglandin H2; PGE2, prostaglandin E2; PGI2, prostacyclin; PGD2, prostaglandin D2; PGF2, prostaglandin F2; PTGER, prostaglandin E receptors; SERCA, sarcoplasmic/ER calcium ATPases; TXA2, thromboxane A2; VEGFA, vascular endothelial cell growth factor. A fully interactive version is available online at http://www.pharmgkb.org/pathway/PA152241951.
See this image and copyright information in PMC

References

    1. Fort J. Celecoxib, a COX-2-specific inhibitor: the clinical data. Am J Orthop (Belle Mead NJ) 1999;28:13–18. - PubMed
    1. [1 June 2011];CELEBREXR Package Insert. Available at http://pfizer.com/files/products/uspi_celebrex.pdf.
    1. Clemett D, Goa KL. Celecoxib: a review of its use in osteoarthritis, rheumatoid arthritis and acute pain. Drugs. 2000;59:957–980. - PubMed
    1. Arber N, Eagle CJ, Spicak J, Racz I, Dite P, Hajer J, et al. Celecoxib for the prevention of colorectal adenomatous polyps. N Engl J Med. 2006;355:885–895. - PubMed
    1. Bertagnolli MM, Eagle CJ, Zauber AG, Redston M, Solomon SD, Kim K, et al. Celecoxib for the prevention of sporadic colorectal adenomas. N Engl J Med. 2006;355:873–884. - PubMed

Publication types

MeSH terms